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Abstract
Background:  The epidermal growth factor (EGF) and EGF receptor (EGFR) families play
important roles in the hyperplastic growth of several tissues as well as tumor growth. Since synovial
hyperplasia in rheumatoid arthritis (RA) resembles a tumor, involvement of the EGF/EGFR families
in RA pathology has been implied. Although several reports have suggested that ErbB2 is the most
important member of the EGFR family for the synovitis in RA, it remains unclear which members
of the EGF family are involved. To clarify the EGF-like growth factors involved in the pathology of
RA, we investigated the expression levels of seven major EGF-like growth factors in RA patients
compared with those in osteoarthritis (OA) patients and healthy control subjects.
Methods: The expression levels of seven EGF-like growth factors and four EGFR-like receptors
were measured in mononuclear cells isolated from bone marrow and venous blood, as well as in
synovial tissues, using quantitative RT-PCR. Further evidence of gene expression was obtained by
ELISAs. The proinflammatory roles were assessed by the growth-promoting and cytokine-inducing
effects of the corresponding recombinant proteins on cultured fibroblast-like synoviocytes (FLS).
Results: Among the seven EGF-like ligands examined, only amphiregulin (AREG) was expressed at
higher levels in all three RA tissues tested compared with the levels in OA tissues. The AREG
protein concentration in RA synovial fluid was also higher than that in OA synovial fluid.
Furthermore, recombinant human AREG stimulated FLS to proliferate and produce several
proinflammatory cytokines, including angiogenic cytokines such as interleukin-8 and vascular
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endothelial growth factor (VEGF), in a dose-dependent manner. The VEGF mRNA levels in RA
synovia and VEGF protein concentrations in RA synovial fluid were significantly higher than those
in the corresponding OA samples and highly correlated with the levels of AREG.
Conclusion: The present findings suggest that AREG functions to stimulate synovial cells and that
elevated levels of AREG may be involved in the pathogenesis of RA.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that is mainly characterized by synovial hyperplasia
and progressive destruction of the affected joints. Acti-
vated synoviocytes in the hypertrophic synovia induce
angiogenesis, and play pivotal roles in the recruitment
and differentiation of inflammatory cells. However, the
driving force of the synovial hyperplasia remains obscure.
The granulomatous tissues of RA synovia, referred to as
pannuses, resemble tumors. Cultured fibroblast-like syn-
oviocytes (FLS) from these pannuses share some features
with transformed cells, i.e. anchorage-independent
growth [1,2] and downregulation of tumor suppressors
[3-5]. Similar to transformed cells, tyrosine-phosphor-
ylated proteins are augmented in RA-FLS, and several
growth factors whose receptors possess tyrosine kinase
activities have been reported to promote the tumor-like
behavior of RA synovial membranes [6-9]. Since platelet-
derived growth factor (PDGF) and fibroblast growth fac-
tor (FGF) stimulate DNA synthesis and proliferation of
FLS cultured in medium containing low concentrations of
serum [10] and histochemical studies have revealed
upregulated expression levels of PDGF and FGF and their
receptors in RA synovial tissues [11-13], these molecules
are considered to be the major contributors to synovial
hyperplasia [2,14].
On the other hand, the proto-oncogene c-erb-B, referred
to as epidermal growth factor (EGF) receptor (EGFR), is a
well-known tyrosine kinase growth factor receptor. Four
members of the EGFR family have been identified to date,
namely c-erb-B/EGFR and its related products ErbB2,
ErbB3 and ErbB4. The family members form homodimers
or heterodimers in various combinations, and exhibit dif-
ferent ligand specificities for the 13 members of the EGF
family [15]. Although expression of ErbB2, but not the
other ErbB-related receptors, has been reported to be aug-
mented in RA synovial tissues [7,16,17], it remains
unknown which members of the EGF family are expressed
in the affected joints and involved in the pathology of RA.
In previous studies, we investigated the involvement of
bone marrow in the pathology of RA. An increase in mye-
loid cells expressing abnormal surface antigens in bone
marrow was associated with the severity of RA [18-23].
Pathogenic synovial fibroblasts may be derived from bone
marrow CD34+ cells in RA [24]. Recently, we identified
RA-associated genes in bone marrow cells using a cDNA
subtraction technique [25]. In that report, we demon-
strated that two EGF-like growth factors, amphiregulin
(AREG) and epiregulin (EREG), were upregulated in RA
bone marrow.
In the present study, we examined the extents of involve-
ment of EGF family members in RA pathology by investi-
gating the expression of seven major EGF-like growth
factors, namely EGF, AREG, EREG, transforming growth
factor α(TGFα), heparin-binding EGF-like growth factor
(HB-EGF), betacellulin (BTC) and neuregulin-1 (NRG1),
in synovial tissues and mononuclear cells isolated from
bone marrow and venous blood. The results revealed that
AREG expression was augmented in all RA tissues and
cells examined. Moreover, the AREG protein concentra-
tion in RA synovial fluid was significantly higher than that
in osteoarthritis (OA) synovial fluid. Recombinant
human AREG stimulated RA-FLS to proliferate and
express several proinflammatory cytokines. These findings
suggest that AREG may play a role in the pathogenesis of
RA.
Methods
Patients and samples
Bone marrow fluid, venous blood and/or synovial tissues
were intraoperatively obtained from 15 RA patients (all
women; mean age ± SD: 59.3 ± 8.7 years) and 12 OA
patients (all women; mean age ± SD: 64.5 ± 11.8 years)
undergoing joint arthroplasty. None of the patients had
taken any medication for at least 1 week before the oper-
ation. The RA and OA patients fulfilled the 1987 revised
criteria of the American College of Rheumatology for the
classification of RA [26] and the diagnostic criteria for OA
[27], respectively. Bone marrow fluid and venous blood
were mixed with heparin and separated by centrifugation
at 1700 g for 15 min. After removal of the plasma, the
blood cells and bone marrow cell fractions were adjusted
to their original volumes with Hank's balanced salt solu-
tion (HBSS) and fractionated by density-gradient centrif-
ugation at 3000 g  for 30 min on Ficoll-Hypaque (GE
Healthcare Bioscience, Tokyo, JPN). Mononuclear cells
were collected from both the bone marrow and peripheral
blood and used for the experiments described below. For
further separation, the collected mononuclear cells were
fractionated by magnetic beads coated with immobilizedJournal of Inflammation 2008, 5:5 http://www.journal-inflammation.com/content/5/1/5
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CD14, CD3 or CD19 antibodies (Miltenyi Biotec, Tokyo,
JPN), since CD14, CD3 and CD19 are lineage-specific
markers for monocytes, T lymphocytes and B lym-
phocytes, respectively. The cell populations fractionated
by these antibodies were measured using flow cytometry,
and confirmed to be > 95% pure. Synovial fluid was
obtained from 24 RA patients and 10 OA patients and
venous blood was obtained from 57 RA patients and 12
OA patients attending the outpatient clinic of our hospi-
tal. Synovial fluid was separated from cells and debris by
centrifugation, and the clear supernatant was collected.
Plasma was collected by centrifuging heparinized blood
as described above. The synovial fluid and plasma sam-
ples were analyzed by ELISAs. All patients and healthy vol-
unteers provided informed consent for participation in
the study, which was approved by the Ethical Committee
of the National Hospital Organization, Sagamihara
National Hospital.
Isolation of FLS and establishment of cell lines
Synovial membranes were minced aseptically and then
digested enzymatically with 1 mg/ml collagenase (Wako,
Osaka, JPN) in Dulbecco's modified Eagle's medium
(DMEM; GIBCO, Grand Island, NY, USA) for 2 h at 37°C.
Single cell suspensions were filtered through a nylon
mesh, seeded in culture dishes containing DMEM supple-
mented with 100 units/ml penicillin, 0.1 mg/ml strepto-
mycin (GIBCO) and 10% fetal bovine serum (FBS;
Hyclone, Logan, UT, USA), and cultured at 37°C in
humidified air containing 7.5% CO2. Since freshly iso-
lated FLS contain many lymphocytes, monocytes and
granulocytes, we used homogeneous fibroblastic cell pop-
ulations after more than 4 passages. In proliferation
assays, FLS cultures were stimulated by various concentra-
tions of recombinant human AREG (R&D Systems,
Tokyo, JPN) for 2 days. Prior to cell harvesting onto glass
fiber disks, FLS were cultured with 3H-thymidine for 18 h.
The radioactivities on the disks were measured using a liq-
uid scintillation counter.
RNA extraction and cDNA synthesis
Total cellular RNAs were extracted using the TRIZOL™ rea-
gent (Invitrogen, Tokyo, JPN) according to the manufac-
turer's instructions. For RNA extraction from synovia,
minced tissues were homogenized in TRIZOL using a Pol-
ytron homogenizer and the extracted RNAs were further
purified using an RNeasy micro kit (QIAGEN, Tokyo,
JPN). In cytokine induction assays, FLS cultures were stim-
ulated by various concentrations of recombinant human
AREG and/or genistein (SIGMA, Tokyo, JPN) for 3 h and
subjected to RNA extraction using the RNeasy micro kit.
First-strand cDNAs were synthesized from 2 μg of total
RNAs by priming with oligo dT and Omniscript™ reverse
transcriptase (QIAGEN) according to the manufacturer's
instructions.
Quantitative RT-PCR
Using real-time PCR, we estimated the mRNA expression
levels of four EGFR family members and seven EGF family
members. In subsequent investigations, the mRNA
expression levels of five proinflammatory cytokines,
namely interleukin (IL)-1β, IL-6, IL-8, tumor necrosis fac-
tor-α (TNF-α) and granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) were measured. The mRNA
expression levels of vascular endothelium growth factor
(VEGF), platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF), a disintegrin and metal-
loproteinase (ADAM) 10 and ADAM17 were also meas-
ured. The primer sequences used were: 5'-
GTGATTCCATCATGTATCCCAGGAG-3', 5'-AGAT-
GCACTGTCCATGCAAACAA-3' (EREG); 5'-CTTCACTGT-
GTGGTGGCAGATG-3', 5'-
ATGCAGTAATGCTTGTATTGCTTGG-3' (BTC); 5'-CAAC-
CAGTGGCTGGTGAGGA-3', 5'-GAGCCCTTATCACT-
GGATACTGGAA-3' (EGF); 5'-
GTGGTGCTGTCGCTCTTGATACTC-3', 5'-TCAAATCCAT-
CAGCACTGTGGTC-3' (AREG); 5'-GGGCATGACTAAT-
TCCCACTGA-3', 5'-GCCCAATCCTAGACGGCAAC-3'
(HB-EGF); 5'-AGATAGACAGCAGCCAACCCTGA-3', 5'-
CTAGGGCCATTCTGCCCATC-3' (TGFα); 5'-AGAATGT-
GCCCATGAAAGTCCAA-3', 5'-GCAGATGCCGGTTAT-
GGTCAG-3' (NRG1); 5'-
GGTGCGAATGACAGTAGCATTATGA-3', 5'-AAAGGT-
GGGCTCCTAACTAGCTGAA-3' (EGFR); 5'-CAGGCAC-
CGCAGCTCATCTA-3', 5'-
TCCCAGGTCACCATCAAATACATC-3' (ErbB2); 5'-
CCCAGCATCTGAGCAAGGGTA-3', 5'-TTTAGGCG-
GGCATAATGGACA-3' (ErbB3); 5'-TGATAGGCCGTT-
GGTTGTCTGA-3', 5'-
CCAGGTAGACATACCCAATCCAGTG-3' (ErbB4); 5'-
CCCACTGAGGAGTCCAACAT-3', 5'-AAATGCTTTCTC-
CGCTCTGA-3' (VEGF); 5'-CTCTGATCATGCTAATGGCT-
GGA-3', 5'-GCTGCAGTTAGCGTCTCATGTGT-3'
(ADAM10); 5'-GTGACATGAATGGCAAATGTGAG-3', 5'-
AGACCCAACGATGTTGTCTGCTA-3' (ADAM17); 5'-
CCCCTGCCCATTCGGAGGAAGAG-3', 5'-TTGGCCAC-
CTTGACGCTGCGGTG-3' (PDGF); 5'-GTTGTGACAAC-
CACAAGCAC-3', 5'-CTCTCACACTATCCACTGGT-3'
(bFGF); 5'-ACACTGCGCCAACACAGAAATTA-3', 5'-TTT-
GCTTGAAGTTTCACTGGCATC-3' (IL-8); 5'-AAGCCA-
GAGCTGTGCAGATGAGTA-3', 5'-
TGTCCTGCAGCCACTGGTTC-3' (IL-6); 5'-CCAG-
GGACAGGATATGGAGCA-3', 5'-TTCAACACGCAG-
GACAGGTACAG-3' (IL-1β); 5'-
CATGATGGCCAGCCACTACAA-3', 5'-ACTGGCTCCCAG-
CAGTCAAAG-3' (GM-CSF); 5'-GACAAGCCTG-
TAGCCCATGTTGTA-3', 5'-CAGCCTTGGCCCTTGAAGA-
3' (TNF-α). Real-time PCR was performed using a Light-
Cycler 2.0 (Roche Diagnostics, Tokyo, JPN) and SYBR
Premix Ex Taq (Takara, Kyoto, JPN) following the manu-
facturers' protocols. The amounts of PCR products wereJournal of Inflammation 2008, 5:5 http://www.journal-inflammation.com/content/5/1/5
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assessed by the fluorescence of SYBR Green intercalated in
the DNA fragments, and melting curves were routinely
recorded to verify the singularity of the products. The
amplified products using each primer pair were cloned
into the pGEM-T vector (Promega, Tokyo, JPN) and plas-
mids linearized by enzymatic digestion were used as
quantification standards. A reference cDNA was used in
every assay to control the precision among assays. The
cDNA levels among the samples were normalized by the
expression level of the internal control gene GAPDH (5'-
GCACCGTCAAGGCTGAGAAC-3', 5'-ATGGTGGTGAA-
GACGCCAGT-3').
ELISAs
The AREG protein concentrations in plasma samples from
57 RA patients, 12 OA patients and 9 healthy volunteers
and synovial fluid samples from 24 RA patients and 8 OA
patients were determined using an AREG Duo-set ELISA
kit (R&D Systems). The protein concentrations of IL-1β,
IL-6, IL-8, TNF-α, GM-CSF and VEGF in culture superna-
tants of RA-FLS stimulated with recombinant human
AREG (R&D Systems) and those of VEGF and IL-8 in syn-
ovial fluid samples from 9 RA patients and 7 OA patients
were determined using a Quantikine ELISA kit (R&D Sys-
tems).
Statistical analysis
Statistical analysis was carried out using the StatView sta-
tistical analysis software (SAS, Cary, NC, USA). Differ-
ences between RA specimens and controls were
determined to be significant when P < 0.05 by the Mann-
Whitney U-test. The effects of AREG on RA-FLS were ana-
lysed by the Mann-Whitney U-test following the Kruskal-
Wallis test. Correlation coefficients (ρ) were calculated by
Spearman's rank correlation method and tested for statis-
tical significance at the 0.05 (two-tailed) level.
Results
Expression profiles of EGF family members in bone marrow 
mononuclearcells (BMMCs)
First, we determined the mRNA expression levels of seven
EGF family members in BMMCs obtained from 9 RA
patients and 10 OA patients (Fig. 1A). EREG was the most
abundantly expressed, and its mRNA level in RA-BMMCs
was significantly higher than that in OA-BMMCs (P =
0.0060). The expression levels of AREG, TGFα and EGF
were about 10-fold lower than that of EREG in OA-
BMMCs, but significantly upregulated in RA-BMMCs (P =
0.0258, P = 0.000045 and P = 0.0140, respectively).
Although the expression of HB-EGF was the next most
abundant in RA-BMMCs, there was no significant differ-
ence between its expression levels in RA- and OA-BMMCs.
The BTC and NRG1 mRNA expression levels were almost
undetectable in both RA- and OA-BMMCs.
Expression profiles of EGF family members in peripheral 
blood mononuclear cells (PBMCs)
Next, we determined the mRNA expression levels of the
seven EGF family members in PBMCs obtained from 8 RA
patients and 7 OA patients (Fig. 1B). EREG, TGFα and
EGF were highly abundantly expressed in PBMCs, and
their mRNA levels in RA- and OA-PBMCs did not differ.
The expression levels of AREG, HB-EGF and NRG1 were
about 10-fold lower than the levels of the highly abun-
dant members in OA-PBMCs. Although AREG and HB-
EGF were markedly upregulated in RA-PBMCs (P = 0.0017
and P = 0.0367, respectively), NRG1 was not upregulated
in RA-PBMCs. BTC was not detected in either type of
PBMCs.
Expression profiles of EGF-like growth factors in synovial 
tissues
Next, we determined the mRNA expression levels of the
seven EGF family members in synovial tissues obtained
from 14 RA patients and 5 OA patients (Fig. 1C).
Although HB-EGF was the most abundantly expressed
and EREG was the next most abundantly expressed in syn-
ovial tissues from both RA and OA joints, their mRNA lev-
els in RA synovia were somewhat lower than those in OA
synovia. On the other hand, AREG expression, which was
1000-fold lower than HB-EGF expression in OA synovia,
was markedly upregulated in RA synovial tissues (P =
0.0110). Expression of EGF, BTC or NRG1 was not
detected in either OA or RA joints. Since only AREG
expression was augmented in BMMCs, PBMCs and syno-
via of RA patients compared with the levels in control
samples among the seven EGF-related growth factors
examined, we narrowed the focus of the study to AREG.
Determination of plasma and synovial fluid concentrations 
of AREG
To confirm whether the protein concentration of AREG
was augmented in RA patients, the AREG concentrations
in plasma and synovial fluid samples were examined by
ELISA. As shown in Fig. 2A, there were no significant dif-
ferences among the AREG protein concentrations in the
RA, OA and healthy control (HC) plasma samples,
whereas the AREG concentration in RA synovial fluid
samples was significantly higher than that in OA synovial
fluid samples. Evaluation of BMMC, PBMC and plasma
samples from 5 RA patients revealed that the AREG mRNA
levels in RA-PBMCs were highly correlated with those in
RA-BMMCs (data not shown), but not correlated with the
plasma concentrations of this protein (Fig. 2B). Besides
transformed cells, AREG-producing cells were previously
reported to be activated monocytes [28] and activated T
lymphocytes [29]. To clarify which lineage of blood cells
expressed AREG in RA, PBMCs from RA patients were frac-
tionated using magnetic beads coated with immobilized
CD14, CD3 or CD19 antibodies. As shown in Fig. 2C,Journal of Inflammation 2008, 5:5 http://www.journal-inflammation.com/content/5/1/5
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mRNA expression levels of EGF-related growth factors in BMMCs (A), PBMCs (B) and synovial tissues (C) Figure 1
mRNA expression levels of EGF-related growth factors in BMMCs (A), PBMCs (B) and synovial tissues (C). The 
results of real-time PCR are shown as box-plots. The log ratio of the mRNA quantities relative to the total RNA amount (A) 
or GAPDH mRNA (B, C) is plotted on the y-axis of each graph. The upper and lower error bars indicate the 90th and 10th 
percentiles, respectively. The upper and lower edges of each box indicate the 75th and 25th percentiles, respectively, and the 
line inside the box shows the median. Genes not detected are shown as ND. The differences between the mRNA levels in the 
RA and control samples were analyzed by the Mann-Whitney U-test, and significant differences are shown by asterisks (*P < 
0.05; **P < 0.01). RA: samples from RA patients; OA: samples from OA patients.
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Amphiregulin expression in peripheral blood and synovial fluid samples Figure 2
Amphiregulin expression in peripheral blood and synovial fluid samples. (A) The concentrations of AREG in plasma 
and synovial fluid samples are plotted as log-values on the y-axis of box-plots. Significant differences are shown by asterisks (**P 
< 0.01). RA: samples from RA patients; OA: samples from OA patients; HC: samples from healthy volunteers. (B) The AREG 
mRNA expression levels in PBMCs and AREG protein concentrations in plasma are shown. Venous blood samples from 6 RA 
patients and 6 healthy volunteers (HC) were separated into plasma and PBMCs. Total RNAs were extracted from PBMCs and 
subjected to cDNA synthesis. The AREG mRNA levels were measured by real-time PCR and normalized by the GAPDH 
mRNA levels. The relative AREG mRNA level relative to the GAPDH mRNA level is plotted as the log ratio on the primary y-
axis (left), while the plasma concentration of AREG protein measured by ELISA is plotted as the log value on the secondary y-
axis (right). The correlation coefficient (ρ) of the protein level in plasma to the mRNA level in PBMCs is -0.378 (P = 0.2104). 
(C) PBMCs from 4 RA patients and 2 HCs were separated by CD14 microbeads, and the AREG mRNA level in each fraction 
was measured by real-time PCR. The log ratio of the AREG mRNA level relative to the GAPDH mRNA level is plotted on the 
y-axis.
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both CD14-positive and CD14-negative fractions of RA-
PBMCs expressed equal amounts of AREG mRNA, and
their levels were markedly higher than that in control
PBMCs. The CD3 and CD19 separations yielded similar
results (data not shown).
Effects of AREG on the proliferation of RA-FLS
To investigate the biological activity of AREG in joints
affected by RA, we assessed the effects of recombinant
human AREG on RA-FLS. Since AREG is a member of the
EGF-like growth factor family, its growth-promoting activ-
ity was measured first. As shown in Fig. 3A, recombinant
human AREG enhanced de novo DNA synthesis by RA-FLS
in a dose-dependent manner. Fig. 3B shows the expres-
sion levels of the four EGFR family members in the cell
lines used in the proliferation assay. In all FLS cell lines,
ErbB2 and EGFR were the predominantly expressed recep-
tors and ErbB3 and ErbB4 were expressed at about 100-
fold lower levels than the most abundant ErbB2 level.
There were no differences among the three RA-FLS lines
and the one OA-FLS line. Although the amounts of radio-
activity incorporated into the RA-FLS lines were higher
than that incorporated into the OA-FLS line, the issue of
whether RA-FLS are more sensitive to AREG than OA-FLS
requires further examination. EGF-like growth factors are
expressed as transmembrane-type precursors, and ectodo-
main shedding by ADAMs is essential for their effects as
well as the expression of their receptors [30,31]. Since
ADAM10 and ADAM17 are known to be sheddases for
EGF-like growth factors, we measured the expression lev-
els of the four EGFR-like receptors and ADAM10 and
ADAM17 in synovial tissues from 10 RA patients and 6
OA patients (Fig. 3C). Similar to the findings for FLS,
EGFR and ErbB2 were the predominantly expressed recep-
tors in synovial tissues and their expression levels were
not augmented in RA samples. Although AREG is sup-
posed to be mainly processed by ADAM17, ADAM17 was
expressed at a lower level than ADAM10, and neither
ADAM10 nor ADAM17 was upregulated in RA synovia.
Effects of AREG on cytokine production by RA-FLS
Next, we tested the expression levels of five proinflamma-
tory cytokines (IL-1β, TNF-α, IL-8, GM-CSF and IL-6) in
RA-FLS stimulated by recombinant AREG. To clarify
whether the recombinant AREG stimulated RA-FLS to pro-
liferate via the induction of other growth factors, we also
tested the expression levels of PDGF, bFGF and VEGF,
which are involved in synovial hyperplasia. Recombinant
AREG upregulated the mRNA expression levels of VEGF,
IL-8, GM-CSF and IL-6 (Fig. 4A), but not those of PDGF,
bFGF, IL-1β or TNF-α (data not shown). Recombinant
AREG stimulated RA-FLS to express these cytokines in a
dose-dependent manner, and the EGFR-tyrosine kinase
inhibitor genistein suppressed the AREG-dependent
expression in a dose-dependent manner. ELISA analysis
revealed elevated levels of VEGF, IL-8, GM-CSF and IL-6
proteins in culture supernatants of AREG-stimulated RA-
FLS (Fig. 4B), consistent with the results of the real-time
PCR. We also tested the expression levels of ADAM10 and
ADAM17 in AREG-stimulated RA-FLS. Contrary to the
effect on the cytokine induction, AREG downregulated
the expression of ADAM17 in a dose-dependent manner,
and the AREG-dependent suppression was abolished by
genistein (Fig. 4C). Analyses of ADAM10 expression pro-
duced similar results to those for ADAM17 (data not
shown).
Correlation between VEGF and AREG expression levels
Since higher inductions of IL-6, IL-8 and GM-CSF than
those induced by AREG have been observed and induc-
tion of VEGF has not yet been observed in our previous
studies [32,33], we hypothesized that AREG would be
closely related to VEGF in RA joints. To examine the rela-
tionship of AREG with this angiogenic factor in affected
joints, VEGF expression was assessed in synovial tissues
from 10 RA patients and 6 OA patients. Fig. 5A shows the
mRNA levels of VEGF measured by real-time PCR. Ikeda
et al. reported that the VEGF165 transcript may be aug-
mented in RA synovial tissues, and that the products of
this transcript may be associated with RA pathology [34].
The primers for the real-time PCR amplification of VEGF
used in our study were also designed to detect VEGF165.
VEGF expression in RA synovia was significantly higher
than that in OA synovia (Fig. 5A, left panel), and highly
correlated with AREG expression (Fig. 5A, right panel).
Fig. 5B shows the VEGF protein concentrations in synovial
fluid samples measured by ELISA. The ELISA system is
able to detect all isoforms of VEGF-A, although it was
designed for VEGF165. Consistent with the results of the
mRNA expression analyses, the VEGF protein levels in RA
synovial fluid samples were significantly higher than
those in OA synovial fluid samples (Fig. 5B, left panel),
and highly correlated with the AREG concentration (Fig.
5B, right panel).
Discussion
Several previous studies have reported the involvement of
c-erb-B family members, especially ErbB2, in the pathol-
ogy of RA. Hallbech et al. showed immunohistochemi-
cally that the expression levels of ErbB2 and TGFα were
augmented in RA synovia [17]. Satoh et al. demonstrated
that ErbB2 was predominant in RA synovia and primary
RA-FLS, but not in OA synovia or primary OA-FLS, and
that a neutralizing antibody against ErbB2 suppressed the
proliferation of primary RA-FLS, but not primary OA-FLS
[16]. In the present study, we investigated which members
of the ErbB family are predominantly expressed in RA-FLS
and RA synovial tissues. Among the four ErbB family
members, the mRNA level of ErbB2 was the highest, fol-
lowed by that of EGFR, while the others were expressed atJournal of Inflammation 2008, 5:5 http://www.journal-inflammation.com/content/5/1/5
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Stimulatory activity of AREG on the proliferation of RA-FLS Figure 3
Stimulatory activity of AREG on the proliferation of RA-FLS. (A) Effect of AREG on the proliferation of RA-FLS. 
Three RA-FLS lines and one OA-FLS line were cultured with the indicated concentrations of AREG. After 24 h of stimulation, 
the cells were labeled with 3H-thymidine for 18 h and then harvested on glass filters with a cell harvester. The incorporated 
radioactivity was measured by liquid scintillation counting. The values are shown as the means ± SD of three independent 
experiments. Significant differences are shown by asterisks (*P < 0.05; **P < 0.01). (B) Expression profiles of EGFR family mem-
bers in FLS. cDNA samples of the four FLS lines used in the proliferation assay were subjected to real-time PCR analysis. (C) 
Expression profiles of the receptors and sheddases of the EGF family in synovia. cDNAs of synovial tissues from 10 RA patients 
and 6 OA patients were subjected to real-time PCR analysis.
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almost undetectable levels in FLS and synovial mem-
branes. While these results are consistent with the previ-
ous report [16], there were no differences in the
expression levels between RA and OA samples. This dis-
crepancy may reflect differences in the synovial speci-
mens, although it will be necessary to confirm this
hypothesis by assessing the ErbB2 protein concentrations
in RA and OA samples. The OA synovial samples used in
the present study were obtained from synovia with villous
formation, rather than from the joint capsule, and thus
our OA samples may be more activated than those used in
the previous study. In any case, ErbB2 and EGFR were con-
firmed to be predominantly expressed in RA-FLS and RA
synovia.
On the other hand, there have been very few reports of the
expression profiles of EGF-like growth factors in RA syno-
via. In the present study, we found that AREG expression,
which was 1000-fold lower than the most abundantly
expressed HB-EGF in OA synovia, was markedly upregu-
lated in RA synovia. Since it was correlated with the
expression of AREG (ρ = 0.532, P = 0.0241), the expres-
sion of TGFα may tend to be augmented in RA synovia, as
reported previously [17].
Since we recently reported augmented expression of AREG
in BMMCs and PBMCs from RA patients [25], we exam-
ined the expression levels of other EGF family members in
the present study. In RA-BMMCs, EGF and TGFα were also
Stimulatory activity of AREG on cytokine production by RA-FLS Figure 4
Stimulatory activity of AREG on cytokine production by RA-FLS. (A) Effects of AREG on cytokine expression in RA-
FLS. Four RA-FLS lines were cultured with the indicated concentrations of recombinant human AREG and/or genistein. After 4 
h of stimulation, total RNAs were extracted and the mRNA levels of PDGF, bFGF, VEGF, IL-1β, IL-6, IL-8, TNF-α and GM-CSF 
were measured by real-time PCR. The results for VEGF, IL-8, GM-CSF and IL-6 are shown. The results for the other molecules 
were omitted from the figure, since AREG had no effect on their expressions. (B) Effects of AREG on cytokine production by 
RA-FLS. Four RA-FLS lines were cultured with the indicated concentrations of AREG for 24 h. The GM-CSF, IL-6, IL-8 and 
VEGF concentrations in the supernatants were measured by ELISA, and are shown as means ± SD. (C) Effects of AREG on the 
expression of sheddases. The same cDNA samples used in panel A were subjected to real-time PCR analysis for ADAM10 and 
ADAM17. The results for ADAM10 were omitted from the figure, since they were similar to those for ADAM17. Each panel 
shows a representative result of three independent experiments. Significant differences from unstimulated cells are shown by 
asterisks (*P < 0.05; **P < 0.01).
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upregulated, similar to AREG and EREG whose aug-
mented expressions were reported in our previous study.
Although there was no significant difference between the
levels of HB-EGF in the RA and OA samples, its high cor-
relations with AREG and EREG (ρ = 0.788, P = 0.0008 and
ρ = 0.823, P = 0.0005, respectively) imply that HB-EGF
may be upregulated in RA. Although EGF and TGFα were
also upregulated in RA, their expression levels showed no
correlations with those of other members. These results
suggest that AREG, EREG and HB-EGF may be regulated
by a common expression-controlling system.
In RA-PBMCs, AREG and HB-EGF were significantly
upregulated, and their expression levels were correlated
with each other (ρ = 0.600, P = 0.0305). Among the seven
EGF family members examined, only AREG expression
was augmented in all three tissues tested in the present
study. To confirm which lineage of blood cells expresses
AREG, PBMCs were further separated into monocyte-, T
lymphocyte- and B lymphocyte-rich fractions. None of
these fractions was enriched in AREG-expressing cells in
healthy controls or RA patients. In our recent report, we
speculated that bone marrow-derived abnormal mono-
cytes expressing AREG may migrate via the blood circula-
Correlation between AREG and VEGF expression levels Figure 5
Correlation between AREG and VEGF expression levels. (A) The VEGF mRNA expression levels in synovia from 10 
RA patients and 6 OA patients were measured by real-time PCR, and are shown by box-plots (left). Significant differences from 
unstimulated cells are shown by asterisks (*P < 0.05). The correlation between the mRNA levels of VEGF and AREG is shown 
by a distribution chart (right). The linear regression coefficient (R2) is 0.496 and the correlation coefficient (ρ) is 0.700 (P = 
0.0067). (B) The concentrations of VEGF in synovial fluids from 7 RA patients and 6 OA patients were measured by ELISA, and 
are shown by box-plots (left). Significant differences from unstimulated cells are shown by asterisks (*P < 0.05). The correlation 
between the protein concentrations of VEGF and AREG is shown by a distribution chart (right), in which R2 is 0.577 and ρ is 
0.772 (P = 0.0075).
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tion, and bring about disease in synovia and/or other
tissues they infiltrated [25]. Although our present findings
strongly support that hypothesis, the abnormal cells
expressing AREG among RA-PBMCs were not restricted to
monocytes. We conclude that they are mononuclear leu-
kocytes and not of a particular lineage.
Herceptin, a specific inhibitor of ErbB2, was reported to
suppress the proliferation of RA-FLS, but not OA-FLS, and
augmented expression of ErbB2 was considered to be a
major contributor to the autonomous proliferation of RA-
FLS [16]. In the present study, EGFR and ErbB2 were
found to be predominantly expressed in synovial tissues
and cultured FLS, with no differences between their
expression levels in RA and OA. Furthermore, the expres-
sion levels of ADAM10 and ADAM17, which are also
important for the functions of EGF-like growth factors,
showed no differences between RA and OA. On the other
hand, the mRNA and protein levels of AREG were upreg-
ulated in RA synovial tissues. Furthermore, recombinant
human AREG enhanced the proliferation of FLS in a dose-
dependent manner. In our study, differences were
detected for EGF-like growth factors between RA and OA
synovia, but not for their receptors or sheddases. AREG
induces tyrosine phosphorylation of EGFR and transduces
a stronger signal when bound to EGFR/ErbB2 heterodim-
ers [15]. It has been reported that synovitis with granulo-
matous hyperplasia occurs in AREG transgenic mice [35].
These findings suggest that overexpression of AREG may
promote the proliferation of synoviocytes in affected
joints of RA patients. We investigated whether recom-
binant AREG induced the expression of PDGF and bFGF,
which are well-known growth factors for hyperplastic pro-
liferation of RA-FLS. We found that AREG had no effects
on the expression of these factors, suggesting that AREG
did not stimulate RA-FLS to proliferate via these growth
factors. However, AREG stimulated RA-FLS to express
VEGF, an angiogenic factor involved in synovial hyperpla-
sia.
A large number of reports have shown that RA-FLS pro-
duce proinflammatory cytokines when stimulated by var-
ious stimuli [36,37]. In addition, we previously reported
that RA-FLS produce proinflammatory cytokines, such as
IL-6, IL-8, GM-CSF, IL-1β and/or TNFα, when co-cultured
with monocytes or lymphocytes [32,33]. Our analyses of
cytokine production in the present study revealed that
AREG enhanced the production of several proinflamma-
tory cytokines (IL-6, IL-8 and GM-CSF) and VEGF in RA-
FLS. Since they were suppressed by an EGFR tyrosine
kinase inhibitor, the AREG-dependent induction of these
cytokines seemed to occur via activation of EGFR/ErbB2.
Interestingly, AREG downregulated the expression of
ADAM10 and ADAM17 in a dose-dependent manner.
These results suggest the presence of negative feedback
regulation of ADAMs via AREG/EGFR signaling. To assess
the involvement of AREG in the elevated expression of
VEGF in affected joints of RA patients, the correlations
between their mRNA levels and protein levels in synovial
fluid samples were analyzed, and good correlations were
found for both the mRNA levels (ρ = 0.700, P = 0.0067)
and protein levels (ρ = 0.772, P = 0.0075). There have
been very few reports about cytokine induction by AREG
to date. The present results suggest that the increased level
of AREG may be involved in the upregulation of VEGF in
RA joints, and demonstrate, for the first time, that AREG
stimulates RA-FLS to produce proinflammatory cytokines,
including angiogenic factors. IL-8 has been reported to be
an angiogenic factor as well as a chemoattractant factor
[38,39]. Although several studies have recently shown
that AREG plays important roles in hyperplasia or angio-
genesis of skin diseases or tumors [40-43], the role of
AREG in RA pathology remains unknown. Ma et al. spec-
ulated on the involvement of AREG in the angiogenesis of
tumors [40]. Although it is known that EGF and TGFα are
potent angiogenic mediators [44,45], the proangiogenic
activity of AREG has not been directly determined to date.
Its induction of angiogenic factors, such as IL-8 and VEGF,
strongly suggests that AREG may be involved in the angio-
genesis of synovial hyperplasia in affected joints of RA
patients.
Myeloid cells expressing abnormal cell surface markers
have been observed in RA bone marrow [18,19] and
reported to be correlated with the disease severity [20-23].
Consistent with these reports, the present study revealed
that several EGF-like growth factors were upregulated in
RA bone marrow cells, suggesting that the onset and/or
progression of chronic synovitis may be influenced by
alterations to the bone marrow in RA patients.
Conclusion
Among the seven EGF-like growth factors, AREG was
upregulated in synovial tissues of RA patients. Recom-
binant human AREG stimulated RA-FLS to proliferate and
produce several proinflammatory cytokines, including
angiogenic factors. These results suggest that the elevated
expression of AREG in synovial tissues may be involved in
RA pathology containing synovial hyperplasia. AREG-
expressing cells were observed in both the blood and bone
marrow of RA patients as well as in RA synovial tissues.
Abnormal leukocytes may lead to the upregulated expres-
sion of AREG in affected joints of RA patients.
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